CVE-2023-40153 — MEDIUM (5.4)

Vulnerability Description

The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injecting an XSS payload into the 'hostname' parameter of the vulnerable software.

CVSS Score

5.4

MEDIUM

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:N

Attack Vector

NETWORK

Attack Complexity

LOW

Privileges Required

LOW

User Interaction

NONE

Scope

UNCHANGED

Confidentiality

LOW

Integrity

LOW

Availability

NONE

Affected Products

Vendor	Product	Versions
Dexma	Dexgate	20130114

Related Weaknesses (CWE)

CWE-79

References

https://www.cisa.gov/news-events/ics-advisories/icsa-23-271-02Third Party AdvisoryUS Government Resource
https://www.cisa.gov/news-events/ics-advisories/icsa-23-271-02Third Party AdvisoryUS Government Resource

FAQ

What is CVE-2023-40153?

CVE-2023-40153 is a vulnerability with a CVSS score of 5.4 (MEDIUM). The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injecting an XSS payload ...

How severe is CVE-2023-40153?

CVE-2023-40153 has been rated MEDIUM with a CVSS base score of 5.4/10. Review the CVSS metrics above for detailed severity breakdown.

Is there a patch for CVE-2023-40153?

Check the references section above for vendor advisories and patch information. Affected products include: Dexma Dexgate.